Table 1: Participant baseline characteristics stratified by time of denosumab injection.

CharacteristicTime of subsequent injection of denosumab
<5 months5–7 months>7 months

Sample size ()1236559
Age, years, mean (SD)67.50 (9.59)68.35 (10.62)64.34 (11.20)
Women, % ()91.67% (11)92.6% (338)91.53% (54)
Proton pump inhibitor (PPI) use, % ()27.27% (3)26.30% (96)22.03% (13)
Selective serotonin reuptake inhibitor (SSRI) use, % ()0.00% (0)6.85% (25)7.02% (4)
Serotonin-norepinephrine reuptake inhibitor (SNRI) use, % ()0.00% (0)1.37% (5)5.17% (3)
Tricyclic antidepressant (TCA) use, % ()9.09% (1)4.11% (15)5.17% (3)
BMD, mean (SD)
 Lumbar spine0.850 (0.149)0.800 (0.131)0.808 (0.101)
 Femoral neck0.629 (0.043)0.623 (0.100)0.619 (0.100)
 History of nonvertebral fracture, % ()41.67% (5)55.34% (202)49.15% (29)
 History of vertebral fracture, % ()16.67% (2)23.56% (86)22.05% (13)